Australian researchers found that T cells engineered to express the dendritic cell growth factor Flt3L overcame an important obstacle to the treatment of solid tumors.
Rights to the antibody candidate JTX-8064 have been transferred from Bristol-Myers Squibb back to Jounce Therapeutics effective June 3rd 2020.
TUM researchers have found that methylglyoxal underlies MDSC-mediated immunosuppression with implications for cancer diagnosis and treatment.
Interim analysis of the ZUMA-5 trial found that Yescarta showed efficacy for treating relapsed or refractory indolent non-hodgkin lymphoma.
The NDA submission is intended to support the approval of Tivozanib as a treatment for adult renal cell carcinoma in the United States.
Tecentriq (atezolizumab) has been approved by the FDA as a first-line treatment for adult PD-L1-high metastatic non-small cell lung cancer.
Oncolytics Biotech has announced a publication demonstrating positive data for Pelareorep, FOLFIRI, and bevacizumab in colorectal cancer.
The phase 3 CheckMate 9LA trial by Bristol Myers Squibb evaluated the efficacy of Opdivo and Yervoy for treating non-small cell lung cancer.
Surface Oncology will contribute anti-CD39 SRF617 and Merck anti-PD-1 Keytruda in the phase 1/1b trial involving patients with solid tumors.